文献速递免疫规划

调控延迟减毒增强表达猪霍乱沙门菌O-多糖的重组鼠伤寒沙门菌疫苗的免疫原性与保护力

Regulated delayed attenuation enhances the immunogenicity and protection provided by recombinant Salmonellaenterica serovar Typhimurium vaccines expressing serovar Choleraesuis O-polysaccharides.
PubMed 文献 · Vaccine · 2018-07-13

本研究用阿拉伯糖依赖的araC PBAD启动子替换crp天然启动子,构建调控延迟减毒的鼠伤寒沙门菌疫苗株SLT31与SLT33,并以直接crp突变株SLT30与SLT32为对照。两种调控延迟减毒株在小鼠组织定植、抗猪霍乱沙门菌LPS抗体应答、组织细菌载量降低及致死剂量攻击保护上均优于对照株(100% vs. 80%或70% vs. 50%),四株疫苗均对鼠伤寒沙门菌攻击提供完全保护。

要点

  • SLT31(pCZ1)与SLT33(pCZ1)为araC PBAD调控crp的延迟减毒株,对照为直接crp突变株SLT30(pCZ1)与SLT32(pCZ1)。
  • 调控延迟减毒株定植小鼠组织更好,抗猪霍乱沙门菌LPS抗体应答更强,组织细菌载量显著降低。
  • 致死剂量猪霍乱沙门菌攻击后保护率为100% vs. 80%或70% vs. 50%,四株疫苗均完全保护鼠伤寒沙门菌攻击。

核心结论

  • 通过araC PBAD调控crp基因实现的调控延迟减毒可增强表达异源OPS的沙门菌载体疫苗的交叉保护。
  • SLT31(pCZ1)是预防鼠伤寒沙门菌和猪霍乱沙门菌感染的良好候选疫苗。

研究设计与样本

  • 构建两株调控延迟减毒株SLT31(Δasd ΔrmlB-rfbP ΔPcrp::T araC PBAD)与SLT33(Δasd ΔrfbP ΔpagL::T araC PBADrfbP ΔPcrp::T araC PBAD),以及两株直接crp突变对照株SLT30(Δasd ΔrmlB-rfbP Δcrp)与SLT32(Δasd ΔrfbP ΔpagL::T araC PBADrfbP Δcrp)。
  • 将表达猪霍乱沙门菌OPS的Asd+质粒pCZ1导入上述菌株,在小鼠免疫系统中评价递送异源OPS的能力。

主要发现

  • SLT30(pCZ1)与SLT31(pCZ1)仅表达异源OPS,SLT32(pCZ1)与SLT33(pCZ1)共表达同源与异源OPS。
  • SLT31(pCZ1)或SLT33(pCZ1)较SLT30(pCZ1)或SLT32(pCZ1)在小鼠组织定植显著更好,免疫后抗猪霍乱沙门菌LPS抗体应答更强。
  • SLT31(pCZ1)或SLT33(pCZ1)免疫较SLT30(pCZ1)或SLT32(pCZ1)免疫显著降低小鼠组织细菌载量,对致死剂量猪霍乱沙门菌攻击保护更强(100% vs. 80%或70% vs. 50%)。
  • 四株疫苗均对鼠伤寒沙门菌攻击提供完全保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Regulated delayed attenuation is a well-studied strategy for retaining the immunogenicity of Salmonella-vectored vaccines. In this study, this strategy was used to optimize two previously constructed recombinant Salmonella enterica serovar Typhimurium vaccines expressing S. Choleraesuis O-polysaccharides (OPS). The novel vaccine strains SLT31 (Δasd ΔrmlB-rfbP ΔPcrp::T araC PBAD) and SLT33 (Δasd ΔrfbP ΔpagL::T araC PBADrfbP ΔPcrp::T araC PBAD) were constructed by replacement of the native crp promoter with the arabinose-dependent araC PBAD promoter. As controls, two vaccine strains with direct crp mutations were also constructed, namely, SLT30 (Δasd ΔrmlB-rfbP Δcrp) and SLT32 (Δasd ΔrfbP ΔpagL::T araC PBADrfbP Δcrp). Then, the ability to deliver the heterologous S. Choleraesuis OPS on the Asd+ plasmid pCZ1 to the mouse immune system was evaluated in the strains with or without regulated delayed attenuation. The SLT30 (pCZ1) and SLT31 (pCZ1) strains expressed only the heterologous OPS, while the SLT32 (pCZ1) and SLT33 (pCZ1) strains co-expressed the homologous and heterologous OPS. The strain SLT31 (pCZ1) or SLT33 (pCZ1), which exhibited regulated delayed attenuation, colonized mouse tissues significantly better and stimulated stronger antibody responses against S. Choleraesuis LPS post immunization than the SLT30 (pCZ1) or SLT32 (pCZ1) strain. Immunization with SLT31 (pCZ1) or SLT33 (pCZ1) resulted in a significant reduction in bacterial loads in mouse tissues and a greater degree of protection against a lethal S. Choleraesuis dose compared with the effects observed after SLT30 (pCZ1) or SLT32 (pCZ1) immunization (100% vs. 80% or 70% vs. 50%, respectively). In addition, all four vaccines conferred complete protection against S. Typhimurium challenge. Overall, our study demonstrates that regulated delayed attenuation via an araC PBAD-regulated crp gene can enhance the cross-protection by Salmonella-vectored vaccines expressing heterologous OPS, and strain SLT31 (pCZ1) is a good candidate vaccine for preventing both S. Typhimurium and S. Choleraesuis infections.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhao X, Liang S, Dai Q, et al. Regulated delayed attenuation enhances the immunogenicity and protection provided by recombinant Salmonellaenterica serovar Typhimurium vaccines expressing serovar Choleraesuis O-polysaccharides. Vaccine. 2018. PMID: 30017143. doi:10.1016/j.vaccine.2018.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。